Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism
October 20, 2022
A benign hematology article, not a large study but an eye opener.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
October 10, 2022
Oleclumab (MEDI9447) is a human IgG1λ mAb that inhibits the function of cluster of differentiation 73 (CD73).8 CD73 is an enzyme found on the surfaces of cancer and immune cells and is involved in conversion of adenosine monophosphate to extracellular adenosine, which has an immunosuppressive effect on the tumor environment.9 CD73 upregulation by tumors has been shown to increase extracellular adenosine production and result in subsequent local immunosuppression in multiple canc
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
October 10, 2022
Another use of genomic testing in prostate cancer, pts with high risk mutation may need systemic therapy in addition to oligometastatic stereotactic radiotherapy, well informed patients with no high risk mutation signature may elect to go under surveillance to avoid side effects of androgen deprivation therapy, this also emphasizes the importance of genomic testing in personalizing pt’s care.
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
October 10, 2022
Another option for HR+ /HER-2 negative pts who failed hormonal therapies, caution to toxicity though esp neutropenia and diarrhea, no OS data yet, will be interesting to know if it worth the adverse events at this stage of disease.
Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial
October 1, 2022
Supportive care trial though negative. No role for high dose steroids here.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
October 1, 2022
A radiation oncology article, would like to hear comments from our colleagues regarding this, It seems the trend in rad onc that shorter course is better.
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
October 1, 2022
Another prognostic marker that can predict added efficacy of therapy in this case bevacizumab.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
October 1, 2022
Coming soon to a pharmacy near you?
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
October 1, 2022
Confirming that RR can be an alternative to R chemotherapy as a first line therapy in advanced stage follicular lymphoma.
Race, Rituxmab and relapse in TTP
September 22, 2022
Interesting food for thought in this ethnic group regarding TTP. Large retrospective review of the TTP registry showing that among races there was no variation in mortality, however African-Americans had a reduced RFS in all metrics. Rituximab was not helpful in 1L therapy in any group. In the 2L setting, Rituximab had a significant RFS benefit in Caucasians but not in African-Americans. It did not seem that access to care was the driver in reduced RFS. African-American’s may also have shorter-lived B-cell depletion from CD20-MAb therapy.
